NRx Pharmaceuticals Announces FDA Approval for Expanded Access Protocol and Addresses Acquisition Dispute
NRx Pharmaceuticals (NASDAQ:NRXP) announced that the FDA approved an Intermediate Population Expanded Access Protocol for its drug NRX-101, which is used in conjunction with Transcranial Magnetic Stimulation. The company also addressed a failed acquisition of Kadima Neuropsychiatry Institute by HOPE Therapeutics and stated it has initiated arbitration proceedings.
Tickers: $HOPE
Topics: depression treatment FDA approval PTSD innovation TMS therapy